Hanging in the balance: KIR and their role in disease

Molecular Interventions

Volumn 5, Issue 4, 2005, Pages 226-240

  Williams, Anthony P ^a   Bateman, Andrew R ^a   Khakoo, Salim I ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOIMMUNITY; BONE MARROW TRANSPLANTATION; CELL SUBPOPULATION; CELL SURFACE; CHROMOSOME 19Q; CHRONIC HEPATITIS; CUTANEOUS T CELL LYMPHOMA; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DECIDUA; GENETIC ANALYSIS; GENETIC TRANSDUCTION; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LYMPHATIC LEUKEMIA; MALARIA; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PREGNANCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PSORIASIS VULGARIS; REVIEW; RHEUMATOID ARTHRITIS; SOLID TUMOR; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TROPHOBLAST; VIRUS INFECTION;

ANIMALS; AUTOIMMUNE DISEASES; CYTOMEGALOVIRUS INFECTIONS; EVOLUTION, MOLECULAR; FEMALE; GENOTYPE; HEMATOLOGIC DISEASES; HEPATITIS C; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV INFECTIONS; HLA ANTIGENS; HUMANS; IMMUNE SYSTEM; KILLER CELLS, NATURAL; MULTIGENE FAMILY; NEOPLASMS; PREGNANCY; RECEPTORS, IMMUNOLOGIC;

EID: 24144434732     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: 10.1124/mi.5.4.6     Document Type: Review

References (130)

1. Karre, K., Ljunggren, H.G., Piontek, G. and Kiessling, R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319, 675-678 (1986). This paper shows that NK cells can reject tumors based on the absence of MHC class I expression and formed the basis for the missing-self hypothesis. It forms the basis for distinguishing NK cell reactivities from T cell reactivity.
2. Trinchieri, G. Biology of natural killer cells. Adv. Immunol. 47, 187-376 (1989).
3. Peritt, D., Robertson, S., Gri, G., Showe, L., Aste-Amezaga, M., and Trinchieri, G. Differentiation of human NK cells into NK1 and NK2 subsets. J. Immunol. 161, 5821-5824 (1998).
4. Ferlazzo, G., Tsang, M.L., Moretta, L., Melioli, G., Steinman, R.M., and Munz, C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 195, 343-351 (2002).
5. Gerosa, F., Baldani-Guerra, B., Nisii, C., Marchesini, V., Carra, G., and Trinchieri, G. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195, 327-333 (2002).
6. Piccioli, D., Sbrana, S., Melandri, E., and Valiante, N.M. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J. Exp. Med. 195, 335-341 (2002).
7. Biron, C.A., Nguyen, K.B., Pien, G.C., Cousens, L.P., and Salazar-Mather, T.P. Natural killer cells in antiviral defense: Function and regulation by innate cytokines. Annu. Rev. Immunol. 17, 189-220 (1999).
8. Salazar-Mather, T.P., Orange, J.S., and Biron, C.A. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways. J. Exp. Med. 187, 1-14 (1998).
9. Biron, C.A., Byron, K.S., and Sullivan, J.L. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320, 1731-1735 (1989).
10. Orange, J.S. Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect. 4, 1545-1558 (2002).
11. Ploegh, H.L. Viral strategies of immune evasion. Science 280, 248-253 (1998).
12. Li, Y. Zhang, T., Ho, C., Orange, J.S., Douglas, S.D., and Ho, W.Z. Natural killer cells inhibit hepatitis C virus expression. J. Leukoc. Biol. 76, 1171-1179 (2004).
13. Bukowski, J.F., Woda, B.A., Habu, S., Okumura, K., and Welsh, R.M. Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. J. Immunol. 131, 1531-1538 (1983).
14. Monteiro, J.M., Harvey, C., and Trinchieri, G. Role of interleukin-12 in primary influenza virus infection. J. Virol. 72, 4825-4831 (1998).
15. Ljunggren, H.G. and Karre, K. In search of the "missing self": MHC molecules and NK cell recognition. Immunol. Today 11, 237-44 (1990). This was the original description of the "missing-self" model, which has formed the basis for our current understanding of NK cell inhibitory receptors.
16. Huard, B. and Fruh, K. A role for MHC class I down-regulation in NK cell lysis of herpes virus-infected cells. Eur. J. Immunol. 30, 509-515 (2000).
17. Pende, D., Accame, L., Pareti, L., Mazzocchi, A., Moretta, A., Parmiani, G., Moretta, L. The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. Eur. J. Immunol. 28, 2384-2394 (1998).
18. Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J.H., Lanier, L.L., and Spies, T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727-729 (1999).
19. Sivori, S., Pende. D., Bottino, C., Marcenaro, E., Pessino, A., Biassoni, R., Moretta, L., Moretta, A. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur. J. Immunol. 29, 1656-1666 (1999).
20. Radaev, S., Rostro, B., Brooks, A.G., Colonna, M., and Sun, P.D. Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3. Immunity 15, 1039-1049 (2001).
21. Cerwenka, A., Bakker, A.B., McClanahan, T., Wagner, J., Wu, J., Phillips, J.H., and Lanier, L.L. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12, 721-727 (2000).
22. Vitale, M., Bottino, C., Sivori, S., Sanseverino, L., Castriconi, R., Marcenaro, E., Augugliaro, R., Moretta, L., and Moretta, A. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complexrestricted tumor cell lysis. J. Exp. Med. 187, 2065-2072 (1998).
23. Moretta, A., Vitale, M., Bottino, C., Orengo, A.M., Morelli, L., Augugliaro, R., Barbaresi, M., Ciccone, E., and Moretta, L. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J. Exp. Med. 178, 597-604 (1993).
24. Moretta, A., Tambussi, G., Bottino, C., Tripodi, G., Merli, A., Ciccone, E., Pantaleo, G., and Moretta, L. A novel surface antigen expressed by a subset of human CD3- CD16+ natural killer cells. Role in cell activation and regulation of cytolytic function. J. Exp. Med. 171, 695-714 (1990).
25. Karlhofer, F.M., Ribaudo, R.K., and Yokoyama, W.M. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature 358, 66-70 (1992).
26. Saleh, A., Davies, G.E., Pascal, V., Wright, P.W., Hodge, D.L., Cho, E.H., Lockett, S.J., Abshari, M., and Anderson, S.K. Identification of probabilistic transcriptional switches in the Ly49 gene cluster: A eukaryotic mechanism for selective gene activation. Immunity 21, 55-66 (2004). An extremely interesting study of how NK cells might express their receptors clonally, without germline rearrangement based on the relative probabilities of transcription factor binding. They show that transcription occurring in the reverse direction of the Ly49 promoter inhibits transcription in the forward direction.
27. Mingari, M.C., Schiavetti, F., Ponte, M. et al. Human CD8+ T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations. Proc. Natl. Acad. Sci. U.S.A. 93, 12433-12438 (1996).
28. Suto, Y., Maenaka, K., Yabe, T., Hirai, M., Tokunaga, K., Tadok, K., and Juji, T. Chromosomal localization of the human natural killer cell class I receptor family genes to 19q13.4 by fluorescence in situ hybridization. Genomics 35, 270-272 (1996).
29. Lanier, L.L., Corliss, B.C., Wu, J., Leong, C., and Phillips, J.H. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 391, 703-707 (1998).
30. Burshtyn, D.N., Scharenberg, A.M., Wagtmann, N., Rajagopalan, S., Berrada, K., Yi, T., Kinet, J.P., and Long, E.O. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity 4, 77-85 (1996).
31. Campbell, K.S., Dessing, M., Lopez-Botet, M., Cella, M. and Colonna, M. Tyrosine phosphorylation of a human killer inhibitory receptor recruits protein tyrosine phosphatase 1C. J. Exp. Med. 184, 93-100 (1996).
32. Colonna, M., Borsellino, G., Falco, M., Ferrara, G.B., and Strominger, J.L. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc. Natl. Acad. Sci. U.S.A. 90, 12000-12004 (1993). This paper describes HLA-C as a ligand for NK cells and demonstrates that there are sub-populations of NK cells that respond differently to different HLA-C alleles.
33. Wagtmann, N., Rajagopalan, S., Winter, C.C., Peruzzi, M., and Long, E.O. Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. Immunity 3, 801-809 (1995).
34. Cella, M., Longo, A., Ferrara, G.B., Strominger, J.L., and Colonna, M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J. Exp. Med. 180, 1235-1242 (1994).
35. Gumperz, J.E., Litwin, V., Phillips, J.H., Lanier, L.L., and Parham, P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J. Exp. Med. 181, 1133-1144 (1995).
36. Dohring, C., Scheidegger, D., Samaridis, J., Cella, M., and Colonna, M. A human killer inhibitory receptor specific for HLA-A. J. Immunol. 156, 3098-3101 (1996).
37. Hansasuta, P., Dong, T., Thananchai, H., Weekes, M., Willberg, C., Aldemir, H., Rowland-Jones, S., and Braud, V.M. Recognition of HLAA3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur. J. Immunol. 34, 1673-1679 (2004).
38. Biassoni, R., Pessino, A., Malaspina, A., Cantoni, C., Bottino, C., Sivori, S., Moretta, L., and Moretta, A. Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur. J. Immunol. 27, 3095-3099 (1997).
39. Kikuchi-Maki, A., Catina, T.L., and Campbell, K.S. Cutting edge: KIR2DL4 transduces signals into human NK cells through association with the Fc receptor gamma protein. J. Immunol. 174, 3859-3863 (2005).
40. Kikuchi-Maki, A., Yusa, S., Catina, T.L., and Campbell, K.S. KIR2DL4 is an IL-2-regulated NK cell receptor that exhibits limited expression in humans but triggers strong IFN-gamma production. J. Immunol. 171, 3415-3425 (2003).
41. Rajagopalan, S. and Long, E.O. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J. Exp. Med. 189, 1093-1100 (1999).
42. EBMT. http://www.ebi.ac.uk/ipd/
43. Shilling, H.G., Guethlein, L.A., Cheng, N.W., Gardiner, C.M., Rodriguez, R., Tyan, D., and Parham, P. Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. J. Immunol. 168, 2307-2315 (2002).
44. Hsu, K.C., Liu, X.R., Selvakumar, A., Mickelson, E., O'Reilly, R.J., and Dupont, B. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J. Immunol. 169, 5118-5129 (2002).
45. Martin, M.P., Bashirova, A., Traherne, J., Trowsdale, J. and Carrington, M. Expansion of the KIR locus by unequal crossing over. J. Immunol. 171, 2192-2195 (2003).
46. Abi-Rached, L. and Parham, P. Natural selection drives recurrent formation of activating killer cell immunoglobulin-like receptor and Ly49 from inhibitory homologues. J. Exp. Med. 201, 1319-1332 (2005).
47. Khakoo, S.I., Thio, C.L., and Martin, M.P. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305, 872-874 (2004). A paper proposing a model of anti-viral NK cell reactivity based on inhibitory, rather than activating, receptor: ligand combinations.
48. Houchins, J.P., Yabe, T., McSherry, C., and Bach, F.H. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J. Exp. Med. 173, 1017-1020 (1991).
49. Valiante, N.M., Uhrberg, M., Shilling, H.G., Lienert-Weidenbach, K., Arnett, K.L., D'Andrea, A., Phillips, J.H., Lanier, L.L., and Parham, P. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7, 739-751 (1997).
50. Shum, B.P., Flodin, L.R., Muir, D.G., Rajalingam, R., Khakoo, S.I., Cleland, S., Guethlein, L.A., Uhrberg, M., and Parham, P. Conservation and variation in human and common chimpanzee CD94 and NKG2 genes. J Immunol 168, 240-252 (2002).
51. Borrego, F., Ulbrecht, M., Weiss, E.H., Coligan, J.E., and Brooks, A.G. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J. Exp. Med. 187, 813-818 (1998).
52. Braud, V.M., Allan, D.S., O'Callaghan, C.A. et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391, 795-799 (1998).
53. Lee, N., Llano, M., Carretero, M., Ishitani, A., Navarro, F., Lopez-Botet, M., and Geraghty, D.E. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl. Acad. Sci. U.S.A. 95, 5199-5204 (1998).
54. Cosman, D., Mullberg, J., Sutherland, C.L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., and Chalupny, N.J. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14, 123-133 (2001).
55. Vance, R.E., Kraft, J.R., Altman, J.D., Jensen, P.E., and Raulet, D.H. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b). J. Exp. Med. 188, 1841-1848 (1998).
56. Shilling, H.G., Young, N., Guethlein, L.A., Cheng, N.W., Gardiner, C.M., Tyan, D., and Parham, P. Genetic control of human NK cell repertoire. J. Immunol. 169, 239-247 (2002).
57. Della Chiesa, M., Vitale, M., Carlomagno, S., Ferlazzo, G., Moretta, L., and Moretta, A. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur. J. Immunol. 33, 1657-1666 (2003).
58. Vitale, M., Della Chiesa, M., Carlomagno, S., Romagnani, C., Thiel, A., Moretta, L., and Moretta, A. The small subset of CD56brightCD16- natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells. Eur. J. Immunol. 34, 1715-1722 (2004).
59. Khakoo, S.I., Rajalingam, R., Shum, B.P. et al. Rapid evolution of NK cell receptor systems demonstrated by comparison of chimpanzees and humans. Immunity 12, 687-698 (2000).
60. Flores-Villanueva, P.O., Yunis, E.J., Delgado, J.C. et al. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc. Natl. Acad. Sci. U.S.A. 98, 5140-5145 (2001).
61. Martin, M.P., Gao, X., Lee, J.H. et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31, 429-434 (2002).
62. Lopez-Vazquez, A., Mina-Blanco, A., Martinez-Borra, J., Njobvu, P.D., Suarez-Alvarez, B., Blanco-Gelaz, M.A., Gonzalez, S., Rodrigo, L., and Lopez-Larrea, C. Interaction between KIR3DL1 and HLA-B*57 supertype alleles influences the progression of HIV-1 infection in a Zambian population. Hum. Immunol. 66, 285-289 (2005).
63. Andre, P., Brunet, C., Guia, S., Gallais, H., Sampol, J., Vivier, E., and Dignat-George, F. Differential regulation of killer cell Ig-like receptors and CD94 lectin-like dimers on NK and T lymphocytes from HIV-1-infected individuals. Eur. J. Immunol. 29, 1076-1085 (1999).
64. Sirianni, M.C., Ensoli, F., Alario, C., Fiorelli, V., Sacco, G., Topino, S., Iebba, F., Mezzaroma, I., and Aiuti, F. Distribution of the natural killer-related receptor for HLA-C during highly active antiretroviral therapy for human immunodeficiency virus infection. Hum. Immunol. 62, 1328-1334 (2001).
65. De Maria, A., Ferraris, A., Guastella, M. et al. Expression of HLA class I-specific inhibitory natural killer cell receptors in HIV-specific cytolytic T lymphocytes: Impairment of specific cytolytic functions. Proc. Natl. Acad. Sci. U.S.A. 94, 10285-10288 (1997).
66. Cohen, G.B., Gandhi, R.T., Davis, D.M., Mandelboim, O., Chen, B.K., Strominger, J.L., and Baltimore, D. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10, 661-71 (1999).
67. Warren, H.S., Campbell, A.J., Waldron, J.C., and Lanier, L.L. Biphasic response of NK cells expressing both activating and inhibitory killer Ig-like receptors. Int. Immunol. 13, 1043-1052 (2001).
68. Alter, H.J. and Seeff, L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome. Semin. Liver Dis. 20, 17-35 (2000).
69. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral Hepat. 6, 35-47 (1999).
70. Scalzo, A.A., Fitzgerald, N.A., Simmons, A., La Vista, A.B., and Shellam, G.R. Cmv-1, a genetic locus that controls murine cytomegalovirus replication in the spleen. J. Exp. Med. 171, 1469-1483 (1990).
71. Winter, C.C., Gumperz, J.E., Parham, P., Long, E.O., and Wagtmann, N. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J. Immunol. 161, 571-577 (1998).
72. Maenaka, K., Juji, T., Nakayama, T. et al. Killer cell immunoglobulin receptors and T cell receptors bind peptide-major histocompatibility complex class I with distinct thermodynamic and kinetic properties. J. Biol. Chem. 274, 28329-28334 (1999).
73. Boyington, J.C., Motyka, S.A., Schuck, P., Brooks, A.G., and Sun, P.D. Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature 405, 537-543 (2000). The first cocrystal of KIR with its HLA-C ligand. This paper provided a structural explanation for many of the biological features of KIR that had been previously observed.
74. Rajagopalan, S. and Long, E.O. Understanding how combinations of HLA and KIR genes influence disease. J. Exp. Med. 201, 1025-1029 (2005).
75. Carr, W.H., Little, A.M., Mocarski, E., and Parham, P. NK cell-mediated lysis of autologous HCMV-infected skin fibroblasts is highly variable among NK cell clones and polyclonal NK cell lines. Clin. Immunol. 105, 126-140 (2002).
76. Guma, M., Angulo, A., Vilches, C., Gomez-Lozano, N., Malats, N., and Lopez-Botet, M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104, 3664-3671 (2004).
77. Gazit, R., Garty, B.Z., Monselise, Y. et al. Expression of KIR2DL1 on the entire NK cell population: A possible novel immunodeficiency syndrome. Blood 103, 1965-1966 (2004).
78. Mohan, K., Moulin, P. and Stevenson, M. M. Natural killer cell cytokine production, not cytotoxicity, contributes to resistance against blood-stage Plasmodium chabaudi AS infection. J. Immunol. 159, 4990-4998 (1997).
79. Artavanis-Tsakonas, K., Eleme, K., McQueen, K.L., Cheng, N.W., Parham, P., Davis, D.M., and Riley, E.M. Activation of a subset of human NK cells upon contact with Plasmodium falciparum-infected erythrocytes. J. Immunol. 171, 5396-5405 (2003).
80. Moffett-King, A., Entrican, G., Ellis, S., Hutchinson, J., and Bainbridge, D. Natural killer cells and reproduction. Trends Immunol. 23, 332-333 (2002).
81. Redman, C.W. and Sargent, I.L. Latest advances in understanding pre-eclampsia. Science 308, 1592-1524 (2005).
82. King, A., Burrows, T.D., Hiby, S.E. et al. Surface expression of HLA-C antigen by human extravillous trophoblast. Placenta 21, 376-387 (2000).
83. King, A., Allan, D.S., Bowen, M. et al. HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells. Eur. J. Immunol. 30, 1623-1631 (2000).
84. Hiby, S.E., Walker, J.J., O'Shaughnessy, K.M., Redman, C.W., Carrington, M., Trowsdale, J., and Moffett, A. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J. Exp. Med. 200, 957-965 (2004).
85. Varla-Leftherioti, M. Role of a KIR/HLA-C allorecognition system in pregnancy. J. Reprod. Immunol. 62, 19-27 (2004).
86. Varla-Leftherioti, M., Spyropoulou-Vlachou, M., Niokou, D. et al. Natural killer (NK) cell receptors' repertoire in couples with recurrent spontaneous abortions. Am. J. Reprod. Immunol. 49, 183-191 (2003).
87. Yen, J.H., Moore, B.E., Nakajima, T., Scholl, D., Schaid, D.J., Weyand, C.M., and Goronzy, J.J. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J. Exp. Med. 193, 1159-1167 (2001). This paper was the first to describe a genetic association of KIR with a human disease. The authors have also shown in vivo data supporting the expression of the disease association genes on T cells.
88. van Bergen, J., Thompson, A., van der Slik, A., Ottenhoff, T.H., Gussekloo, J., and Koning, F. Phenotypic and functional characterization of CD4 T cells expressing killer Ig-like receptors. J. Immunol. 173, 6719-6726 (2004).
89. null T cells clonally expanded in rheumatoid arthritis. J. Immunol. 165, 1138-1145 (2000).
90. Snyder, M.R., Nakajima, T., Leibson, P.J., Weyand, C.M., and Goronzy, J.J. Stimulatory killer Ig-like receptors modulate T cell activation through DAP12-dependent and DAP12-independent mechanisms. J. Immunol. 173, 3725-3731 (2004).
91. Nakajima, T., Goek, O., Zhang, X., Kopecky, S.L., Frye, R.L., Goronzy, J.J., and Weyand, C.M. De novo expression of killer immunoglobulin-like receptors and signaling proteins regulates the cytotoxic function of CD4 T cells in acute coronary syndromes. Circ. Res. 93, 106-113 (2003).
92. Luszczek, W., Manczak, M., Cislo, M., Nockowski, P., Wisniewski, A., Jasek, M., and Kusnierczyk, P. Gene for the activating natural killer cell receptor, KIR2DS1, is associated with susceptibility to psoriasis vulgaris. Hum. Immunol. 65, 758-766 (2004).
93. Suzuki, Y., Hamamoto, Y., Ogasawara, Y., Ishikawa, K., Yoshikawa, Y., Sasazuki, T., and Muto, M. Genetic polymorphisms of killer cell immunoglobulin-like receptors are associated with susceptibility to psoriasis vulgaris. J. Invest. Dermatol. 122, 1133-1136 (2004).
94. Nelson, G.W., Martin, M.P., Gladman, D., Wade, J., Trowsdale, J., and Carrington, M. Heterozygote advantage in autoimmune disease: Hierarchy of protection/susceptibility conferred by HLA and Killer Ig-Like receptor combinations in psoriatic arthritis. J. Immunol. 173, 4273-4276 (2004). This paper proposes a model for autoimmunity based on activating and inhibitory KIR genotypes, as a type of "molecular rheostat."
95. van der Slik, A.R., Koeleman, B.P., Verduijn, W., Bruining, G.J., Roep, B.O., and Giphart, M.J. KIR in type 1 diabetes: Disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes 52, 2639-2642 (2003).
96. Momot, T., Koch. S., Hunzelmann, N., Krieg, T., Ulbricht, K., Schmidt, R.E., and Witte, T. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum. 50, 1561-1565 (2004).
97. Loughran, T.P., Jr. Clonal diseases of large granular lymphocytes. Blood 82, 1-14 (1993).
98. Rabbani, G.R., Phyliky, R.L., and Tefferi, A. A long-term study of patients with chronic natural killer cell lymphocytosis. Br. J. Haematol. 106, 960-966 (1999).
99. Morice, W.G., Kurtin, P.J., Leibson, P.J., Tefferi, A., and Hanson, C.A. Demonstration of aberrant T-cell and natural killer-cell antigen expression in all cases of granular lymphocytic leukaemia. Br. J. Haematol. 120, 1026-1036 (2003).
100. Nowakowski, G.S., Morice, W.G., Phyliky, R.L., Li, C.Y., and Tefferi, A. Human leucocyte antigen class I and killer immunoglobulin-like receptor expression patterns in T-cell large granular lymphocyte leukaemia. Br. J. Haematol. 128, 490-492 (2005).
101. Handgretinger, R., Geiselhart, A., Moris, A., Grau, R., Teuffel, O., Bethge, W., Kanz, L., and Fisch, P. Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N. Engl. J. Med. 340, 278-284 (1999).
102. Casado, L.F., Granados, E., Algara, P., Navarro, F., Martinez-Frejo, M.C., Lopez-and Botet, M. High expression of the ILT2 (LIR-1) inhibitory receptor for major histocompatibility complex class I molecules on clonal expansions of T large granular lymphocytes in asymptomatic patients. Haematologica 86, 457-463 (2001).
103. Zambello, R., Falco, M., Della Chiesa, M. et al. Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. Blood 102, 1797-1805 (2003).
104. Epling-Burnette, P.K., Painter, J.S., Chaurasia, P., Bai, F., Wei, S., Djeu, J.Y., and Loughran, T.P. Jr. Dysregulated NK receptor expression in patients with lymphoproliferative disease of granular lymphocytes. Blood 103, 3431-3439 (2004).
105. + cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor. Blood 97, 1388-1391 (2001).
106. Poszepczynska-Guigne, E., Schiavon, V., D'Incan, M. et al. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome. J. Invest. Dermatol. 122, 820-823 (2004).
107. Wechsler, J. Bagot, M., Nikolova, M., Parolini, S., Martin-Garcia, N., Boumsell, L., Moretta, A., and Bensussan, A. Killer cell immunoglobulinlike receptor expression delineates in situ Sezary syndrome lymphocytes. J. Pathol. 199, 77-83 (2003).
108. Costello, R.T., Sivori, S., Marcenaro, E. et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99, 3661-3667 (2002).
109. Verheyden, S., Bernier, M. and Demanet, C. Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia 18, 2002200-7 (2004).
110. Lopez-Vazquez, A., Rodrigo, L., Martinez-Borra, J. et al. Protective effect of the HLA-Bw4I80 epitope and the Killer Cell Immunoglobulin-Like Receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J. Infect. Dis. 192, 162-165 (2005).
111. Naumova, E., Mihaylova, A., Stoitchkov, K., Ivanova, M., Quin, L., and Toneva, M. Genetic polymorphism of NK receptors and their ligands in melanoma patients: Prevalence of inhibitory over activating signals. Cancer Immunol. Immunother. 54, 172-178 (2005).
112. Norris, S., Doherty, D.G., Curry, M., McEntee, G., Traynor, O., Hegarty, J.E., and O'Farrelly, C. Selective reduction of natural killer cells and T cells expressing inhibitory receptors for MHC class I in the livers of patients with hepatic malignancy. Cancer Immunol. Immunother. 52, 53-58 (2003).
113. Sandel, M.H., Speetjens, F.M., Menon, A.G. et al. Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol. Immunol. 42, 541-546 (2005).
114. Ikeda, H., Lethe, B., Lehmann, F. et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6, 199-208 (1997).
115. Bakker, A.B., Phillips, J.H., Figdor, C.G., and Lanier, L.L. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. J. Immunol. 160, 5239-5245 (1998).
116. Wu, J.D., Higgins, L.M., Steinle, A., Cosman, D., Haugk, K., Plymate, S.R. Prevalent expression of the immunostimulatory MHC class I chainrelated molecule is counteracted by shedding in prostate cancer. J. Clin. Invest. 114, 560-568 (2004).
117. Groh, V., Wu, J., Yee, C., and Spies, T. Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734-738 (2002).
118. Ruggeri, L., Capanni, M., Casucci, M. et al. Role of natural killer cell allo-reactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood, 94, 333-9 (1999).
119. Ruggeri, L., Capanni, M., Urbani, E. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097-2100 (2002). This paper demonstrated the role of NK cell autoreactivity following bone marrow transplantation, and showed that the potential for NK cell alloreactivity correlated with a multilevel therapeutic benefit in haploidentical bne marrow transplantation for AML.
120. Hsu, K.C., Keever-Taylor, C.A., Wilton, A., Pinto, C., Heller, G., Arkun, K., O'Reilly, R.J., Horowitz, M.M., Dupont, B. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105, 4878-84 (2005).
121. Verheyden, S., Schots, R., Duquet, W., and Demanet, C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 19, 1446-1451 (2005).
122. Asai, O., Longo, D.L., Tian, Z.G., Hornung, R.L., Taub, D.D., Ruscetti, F.W., and Murphy, W.J. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J. Clin. Invest. 101, 1835-1842 (1998).
123. Shlomchik, W.D., Couzens, M.S., Tang, C.B., McNiff, J., Robert, M.E., Liu, J., Shlomchik, M.J., and Emerson, S.G. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285, 412-415 (1999).
124. Giebel, S., Locatelli, F., Lamparelli, T. et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102, 814-819 (2003).
125. Davies, S.M., Ruggieri, L., DeFor, T., Wagner, J.E., Weisdorf, D.J., Miller, J.S., Velardi, A., and Blazar, B.R. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100, 3825-3827 (2002).
126. De Santis, D., Bishara, A., Witt, C.S., Nagler, A., Brautbar, C., Slavin, S., and Christiansen, F.T. Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. Tissue Antigens 65, 519-528 (2005).
127. Miller, J.S., Soignier, Y., Panoskaltsis-Mortari, A. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051-3057 (2005). This paper demonstrates that it is safe to adoptively transfer alloreactive NK cells into patients with malignancy.
128. Markel, G., Gruda, R., Achdout, H., Katz, G., Nechama, M., Blumberg, R.S., Kammerer, R., Zimmermann, W., and Mandelboim, O. The critical role of residues 43R and 44Q of carcinoembryonic antigen cell adhesion molecules-1 in the protection from killing by human NK cells. J. Immunol. 173, 3732-3739 (2004).
129. Zhang, C., Zhang, J., Sun, R., Feng, J., Wei, H., and Tian, Z. Opposing effect of IFNgamma and IFNalpha on expression of NKG2 receptors: Negative regulation of IFNgamma on NK cells. Int. Immunopharmacol. 5, 1057-1067 (2005).
130. Imai, C., Iwamoto, S., and Campana, D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106, 376-383 (2005).